| Guideline Page and Request | Panel Discussion/References | Institution Vote | | | |
|---|---|---|---|---|---|
| | | YES | NO | ABSTAIN | ABSENT |
| MGF-4<br>Internal request:<br><br>Panel comment to consider including tbo-filgrastim as a therapeutic myeloid growth factor option for patient who present with febrile neutropenia, if they did not receive prophylactic G-CSF and there are risk factors present for an infection-associated complication. | Based on the discussion, the panel consensus was to include tbo-filgrastim as a therapeutic MGF option for patient who present with febrile neutropenia, if they did not receive prophylactic G-CSF and there are risk factors present for an infection-associated complication. This is a category 2A recommendation. | 17 | 1 | 0 | 9 |
| MGF-4<br>Internal request:<br><br>Institutional review comment to consider including GM-CSF as a therapeutic option for patients who present with acute exposure to myelosuppressive doses of RT, based on the FDA approved indication. | Based on the discussion, the panel consensus supported the inclusion of the following growth factors as therapeutic options for patients who present with acute exposure to myelosuppressive doses of RT:<br>• Filgrastim<br>• Filgrastim-sndz<br>• Filgrastim-aafi<br>• Tbo-filgrastim<br>• Pegfilgrastim<br>• Pegfilgrastim-jmdb<br>• Sargramostim | <br><br><br>18<br>18<br>18<br>17<br>18<br>18<br>17 | <br><br><br>0<br>0<br>0<br>1<br>0<br>0<br>1 | <br><br><br>0<br>0<br>0<br>0<br>0<br>0<br>0 | <br><br><br>9<br>9<br>9<br>9<br>9<br>9<br>9 |
| MGF-A<br>Internal request:<br><br>Panel comment to consider the inclusion of bone cancer regimens in the list of examples of disease settings and chemotherapy regimens with a high/intermediate risk for febrile neutropenia. | Based on the discussion, the panel consensus was to include the following bone cancer regimens in the list of examples of disease settings and chemotherapy regimens with a high-risk (>20%) for febrile neutropenia:<br>• VAI (vincristine, doxorubicin or dactinomycin, ifosfamide)<br>• VDC-IE (vincristine, doxorubicin or dactinomycin, and cyclophosphamide alternating with ifosfamide and etoposide)<br>• VIDE (vincristine, ifosfamide, doxorubicin or dactinomycin, etoposide)<br>The panel consensus was to include the following bone cancer regimens in the list of examples of disease settings and chemotherapy regimens with an intermediate-risk (10-20%) for febrile neutropenia:<br>• Cisplatin/doxorubicin<br>• VDC (cyclophosphamide, vincristine, doxorubicin or dactinomycin) | 18<br><br><br><br><br><br><br><br><br>18 | 0<br><br><br><br><br><br><br><br><br>0 | 0<br><br><br><br><br><br><br><br><br>0 | 9<br><br><br><br><br><br><br><br><br>9 |